Medeon Biodesign, Inc. (6499.TWO)
- Previous Close
42.40 - Open
43.00 - Bid 42.35 x --
- Ask 42.40 x --
- Day's Range
42.25 - 43.00 - 52 Week Range
39.45 - 60.86 - Volume
10,199 - Avg. Volume
110,685 - Market Cap (intraday)
3.903B - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
-- - EPS (TTM)
-12.87 - Earnings Date --
- Forward Dividend & Yield 0.50 (1.18%)
- Ex-Dividend Date Aug 23, 2023
- 1y Target Est
--
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in Taiwan and the United States. The company focuses on developing devices for minimally invasive surgeries, such as Duett, a vascular graft system; ClickClean, a solution to view throughout laparoscopic surgeries; AbClose to prevent port site herniation caused by improper closure; UroCross, an expander system; PUMA, a solution to treat orthopedic extremity injuries; and Cross-Seal, a large-bore closure device. It is involved in medical device contract manufacturing, equity investment and commerce of medical devices, manufacturing and sale of injection molding and components of medical devices. Medeon Biodesign, Inc. was incorporated in 2012 and is headquartered in Taipei, Taiwan.
www.medeonbio.comRelated News
Performance Overview: 6499.TWO
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6499.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6499.TWO
Valuation Measures
Market Cap
3.89B
Enterprise Value
1.74B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.74
Price/Book (mrq)
1.54
Enterprise Value/Revenue
9.79
Enterprise Value/EBITDA
-1.57
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.46%
Return on Equity (ttm)
-42.09%
Revenue (ttm)
196.26M
Net Income Avi to Common (ttm)
-1.2B
Diluted EPS (ttm)
-12.87
Balance Sheet and Cash Flow
Total Cash (mrq)
2.14B
Total Debt/Equity (mrq)
7.87%
Levered Free Cash Flow (ttm)
-455.87M
Research Analysis: 6499.TWO
Company Insights: 6499.TWO
6499.TWO does not have Company Insights